FINWIRES · TerminalLIVE
FINWIRES

Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says

By

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.

Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a "jewel" at about 4.4x trailing sales, the analyst said.

It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.

"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated," the analyst added.

RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.

Price: $44.78, Change: $+0.04, Percent Change: +0.09%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC